


AMENDMENTS TO THE CLAIMS

1. (Currently amended) A pharmaceutical composition comprising a compound having the formula:



wherein

each of R_1 , R_2 , R_4 , and R_5 is independently selected from the group consisting of hydrogen, hydroxyl, halogens, and alkoxy;

R_1 is selected from the group consisting of $N(CH_3)_2$, phenyl, and halogens, ~~and~~ alkoxy;

R_6 is selected from the group consisting of $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, and CH_3 ;

R_7 is either hydrogen or an alkyl group; and

the bond (a) is either a single or double bond; and

a pharmaceutically acceptable carrier.

2. (Previously presented) The pharmaceutical composition of claim 1, wherein the heterocyclic ring has been substituted with a benzyl ring.

3. (Previously presented) The pharmaceutical composition of claim 1, wherein each of R_1 , R_2 , R_4 , and R_5 are hydrogen;

R_3 is bromine;

R_6 is $\text{CH}(\text{CH}_3)_2$;

R_7 is hydrogen; and

the bond (a) is a double bond.

4. (Previously presented) The pharmaceutical composition of claim 1, wherein each of R_1 , R_2 , R_4 , and R_5 are hydrogen;

R_3 is chlorine;

R_6 is $\text{CH}(\text{CH}_3)_2$;

R_7 is hydrogen; and

the bond (a) is a double bond.

5. (Previously presented) The pharmaceutical composition of claim 1, wherein each of R_1 , R_2 , R_3 , R_4 , and R_5 are hydrogen;

R_6 is $\text{CH}(\text{CH}_3)_2$;

R_7 is hydrogen; and

the bond (a) is a double bond.

6. (Previously presented) The pharmaceutical composition of claim 1, wherein each of R_1 , R_2 , R_4 , and R_5 are hydrogen;

R_3 is $\text{N}(\text{CH}_3)_2$;

R_6 is $\text{CH}(\text{CH}_3)_2$;

R_7 is hydrogen; and

the bond (a) is a double bond.

7. (Currently amended) The pharmaceutical composition of claim 1, wherein in said compound the alkoxyl of R₁, R₂, R₄, or R₅ ~~or R₃~~ contains 10 or fewer carbons.

8. (Currently amended) The pharmaceutical composition of claim 7, wherein in said compound the alkoxyl of R₁, R₂, R₄, or R₅ ~~or R₃~~ contains 4 or fewer carbons.

9. (Currently amended) The pharmaceutical composition of claim 8, wherein in said compound the alkoxyl of R₁, R₂, R₄, or R₅, or R₃ is a methoxyl.

10. (Currently amended) A method for treating cancer in a subject, said method comprising administering to said subject a pharmaceutical composition of claim 1, wherein said cancer is selected from the group consisting of prostate cancer, breast cancer, gastrointestinal cancer, non-small cell lung cancer, colon cancer, melanoma, ovarian cancer, stomach cancer, a brain tumor, a leukemia, a lymphoma, and a carcinoma.

11. (Previously presented) The method of claim 10, wherein said pharmaceutical composition is the pharmaceutical composition of claim 3.

12. (Previously presented) The method of claim 10, wherein said pharmaceutical composition is the pharmaceutical composition of claim 4.

13. (Previously presented) The method of claim 10, wherein said pharmaceutical composition is the pharmaceutical composition of claim 5.

14. (Previously presented) The method of claim 10, wherein said pharmaceutical composition is the pharmaceutical composition of claim 6.

15. (Cancelled)

16. (Previously presented) The method of claim 10, wherein said subject is a mammal.

17. (Previously presented) The method of claim 16, wherein said subject is a human.

18-29. (Cancelled)